Gumming Up the Works: DNA Polymers as HCV Entry Inhibitors

Gastroenterology

Volumn 137, Issue 2, 2009, Pages 427-430

  Counihan, Natalie A ^a   Lindenbach, Brett D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN 1; DNA; GLYCOPROTEIN; GLYCOSAMINOGLYCAN; HEPARIN; INTERFERON; LECTIN; LOW DENSITY LIPOPROTEIN; MEMBRANE FUSION PROTEIN; OCCLUDIN; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; RIBAVIRIN; SCAVENGER RECEPTOR BI; VERY LOW DENSITY LIPOPROTEIN; VIRUS RECEPTOR;

ANTIBIOTIC PROPHYLAXIS; CELL SURFACE; DRUG EFFICACY; EDITORIAL; ENDOSOME; GENE SEQUENCE; HEPATITIS C; HOST CELL; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; RISK FACTOR; RNA VIRUS; TREATMENT RESPONSE; VIRUS ATTACHMENT; VIRUS REPLICATION;

EID: 67650935408     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.06.018     Document Type: Editorial

References (26)

1. Matsumura T., Hu Z., Kato T., et al. Amphipathic DNA polymers inihibit hepatitis C virus infection by blocking viral entry. Gastroenterology 137 (2009) 673-681
2. Pileri P., Uematsu Y., Campagnoli S., et al. Binding of hepatitis C virus to CD81. Science 282 (1998) 938-941
3. Barth H., Schafer C., Adah M.I., et al. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 278 (2003) 41003-41012
4. Koutsoudakis G., Kaul A., Steinmann E., et al. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol 80 (2006) 5308-5320
5. Agnello V., Abel G., Elfahal M., et al. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A 96 (1999) 12766-12771
6. Germi R., Crance J.M., Garin D., et al. Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption. J Med Virol 68 (2002) 206-215
7. Meyer K., Basu A., and Ray R. Functional features of hepatitis C virus glycoproteins for pseudotype virus entry into mammalian cells. Virology 276 (2000) 214-226
8. Cormier E.G., Durso R.J., Tsamis F., et al. L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus. Proc Natl Acad Sci U S A 101 (2004) 14067-14072
9. Pohlmann S., Zhang J., Baribaud F., et al. Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol 77 (2003) 4070-4080
10. Gardner J.P., Durso R.J., Arrigale R.R., et al. L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. Proc Natl Acad Sci U S A 100 (2003) 4498-4503
11. Lozach P.Y., Amara A., Bartosch B., et al. C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles. J Biol Chem 279 (2004) 32035-32045
12. Lozach P.Y., Lortat-Jacob H., de Lacroix de Lavalette A., et al. DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J Biol Chem 278 (2003) 20358-20366
13. Bartosch B., Vitelli A., Granier C., et al. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 278 (2003) 41624-41630
14. Cormier E.G., Tsamis F., Kajumo F., et al. CD81 is an entry coreceptor for hepatitis C virus. Proc Natl Acad Sci U S A 101 (2004) 7270-7274
15. Zhang J., Randall G., Higginbottom A., et al. CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol 78 (2004) 1448-1455
16. Scarselli E., Ansuini H., Cerino R., et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 21 (2002) 5017-5025
17. Zeisel M.B., Koutsoudakis G., Schnober E.K., et al. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology 46 (2007) 1722-1731
18. Evans M.J., von Hahn T., Tscherne D.M., et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446 (2007) 801-805
19. Ploss A., Evans M.J., Gaysinskaya V.A., et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457 (2009) 882-886
20. Catanese M.T., Graziani R., von Hahn T., et al. High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol 81 (2007) 8063-8071
21. Berstein D.I., Goyette N., Cardin R., et al. Amphipathic DNA polymers exhibit antiherpetic activity in vitro and in vivo. Antimicrobial Agents and Chemotherapy 52 (2008) 2727-2733
22. Guzman E., Cheshenko N., Shende V., et al. Amphipathic DNA polymers are candidate vaginal mircobicides and block herpes simplex virus binding, entry and viral gene expression. Antiviral Therapy 12 (2007) 1147-1156
23. Kocisko D.A., Vaillant A., Lee K.S., et al. Potent antiscrapie activities of degenerate phosphorothioate oligonuclotides. Antimicrob Agents Chemother 50 (2006) 1034-1044
24. Lee A.M., Rojek J.M., Gundersen A., et al. Inhibition of cellular entry of lymphocytic choriomeningitis virus by amphipathic DNA polymers. Virology 372 (2008) 107-117
25. Vaillant A., Juteau J.-M., Lu H., et al. Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation. Antimicrobial Agents and Chemotherapy 50 (2006) 1393-1401
26. Meuleman P., Hesselgesser J., Paulson M., et al. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 48 (2008) 1761-1768